Investigation of CoQ10 effect on acute myeloid leukemia

Investigation of CoQ10 effect on miR-155, miR-146a, and miR-196a expression level in patients with acute myeloid leukemia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190924044867N2

Enrollment

Registered

2022-12-25

Start date

2020-06-04

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia. Acute myeloid leukemia with multilineage dysplasia

Interventions

Intervention 1: In the present randomized clinical trial, an intervention group of 32 patients received a loading dose of 200 mg of CoQ10 (Brest Health, USA) two days before the chemotherapy procedure

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age above 18 years, AML confirmation by hematologist using Wright-Giemsa staining, Sudan Black, subtype confirmation by flow cytometry test, having chemotherapy conditions

Exclusion criteria

Exclusion criteria: Receiving any antioxidant supplements within three months before the start of chemotherapy, malignancies other than AML, cases of previous disease or infection, autoimmune disease, cancer, AIDS, receiving any previous chemotherapy

Design outcomes

Primary

Measure	Time frame
MiR-155. Timepoint: Before and two months after the intervention. Method of measurement: Real time PCR.;MiR-146a. Timepoint: Before and two months after the intervention. Method of measurement: Real time PCR.;MiR-196a. Timepoint: Before and two months after the intervention. Method of measurement: Real time PCR.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Moasser

Shiraz University of Medical Sciences

emoasser@sums.ac.ir+98 71 3612 2263

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026